<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142297</url>
  </required_header>
  <id_info>
    <org_study_id>08-0156H</org_study_id>
    <nct_id>NCT01142297</nct_id>
  </id_info>
  <brief_title>Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Controlled Trial Comparing the Stability of SLA Implants and SLActive Implants Using Resonance Frequency Analysis for Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the patterns of dental implant stabilization between a standard and&#xD;
      chemically modified implant surface in patients with type 2 diabetes. It is hypothesized that&#xD;
      the chemically modified surface will enhance early healing events (first 4 months following&#xD;
      placement)in diabetes patients with compromises in rate of implant integration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized study design whereby type 2 diabetic patients will receive 2&#xD;
      implants in the mandible or maxilla to assess implant integration. One implant will be a&#xD;
      regular SLA implant; the other will have a SLActive surface. The primary objective of this&#xD;
      randomized controlled study is to evaluate the stability of Straumann 4.1 mm diameter&#xD;
      implants in the posterior mandible or maxilla of type 2 diabetic patients during the first 12&#xD;
      weeks after implantation using resonance frequency analysis. The control implant is a&#xD;
      standard Straumann implant with an SLA® surface and the test implant the same implant design&#xD;
      with SLActive® surface. Assessments will utilize resonance frequency analysis (RFA), as a&#xD;
      measure of implant integration, and clinical outcomes of implant success. This study will&#xD;
      enroll type 2 diabetes patients having glycated hemoglobin (HbA1c) levels from 8.0% to 12% at&#xD;
      baseline.&#xD;
&#xD;
      The primary objective is to test for statistically significant differences in ISQ values&#xD;
      between the test and control implants at 2, 3, 4, 6, 7, 8 weeks and 3 months after surgery.&#xD;
      If a difference of 2 Osstell RFA ISQ units is detected at any time point it will be&#xD;
      considered that the implant having achieved the higher value is better osseointegrated. This&#xD;
      split-mouth study design will assess changes in implant stability from baseline as the&#xD;
      primary outcome at the implant level. This study will require 20 patients to detect this&#xD;
      difference (SD=2.0 ISQ units) with a power of 80% at the P=0.05 level.&#xD;
&#xD;
      Secondary objectives include:&#xD;
&#xD;
        -  Implant survival and implant success at 1-year post loading.&#xD;
&#xD;
        -  The nature and frequency of adverse events/complications between the 2 groups will be&#xD;
           compared.&#xD;
&#xD;
        -  Prosthesis success&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Stability Quotient (ISQ)</measure>
    <time_frame>4 months</time_frame>
    <description>resonance frequency analysis employed to determine implant stability quotient on a 1-100 point scale with 100 representing the greatest stability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success of Implants</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Partially Edentulous Mandible</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>dental implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard SLA surface and chemically modified surface</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>dental implant and modified dental implant</intervention_name>
    <description>standard SLA surface and chemically modified surface</description>
    <arm_group_label>dental implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females must be at least 18 years of age, and having a diagnosis of type 2&#xD;
             diabetes mellitus occurring over 1 year prior to enrollment (self-reported and&#xD;
             verified with physician report, test results, and/or treatment record)&#xD;
&#xD;
          -  Type 2 diabetic patients may be on a modified diet, oral medication, insulin, or&#xD;
             combination therapies&#xD;
&#xD;
          -  Glycated hemoglobin A1c (HbA1c) levels of at least 8.0% up to and including 12.0% as&#xD;
             reported within 4 weeks of implant placement&#xD;
&#xD;
          -  Have at least two missing teeth in the posterior mandible in FDI positions 4, 5, 6, or&#xD;
             7&#xD;
&#xD;
          -  The tooth at the implant site must have been extracted or lost at least 4 months&#xD;
             before the date of implantation&#xD;
&#xD;
          -  Adequate bone quantity at the implant site to permit the insertion of a Straumann&#xD;
             Standard or Standard Plus 4.1 mm diameter implant at least 8 mm in length without the&#xD;
             use of concurrent bone augmentation techniques, i.e. Implant insertion sites must have&#xD;
             sufficient bone height such that the implant will not encroach on vital structures and&#xD;
             sufficient width that a minimum of 1 mm lingual and buccal bone will remain&#xD;
&#xD;
          -  Patients must have signed the informed consent form. They must be committed to the&#xD;
             study. If the treating clinicians doubt that the patient is willing or will be able to&#xD;
             attend all study follow-up visits then the patient should not be admitted to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of systemic disease other than type 2 diabetes mellitus that&#xD;
             may preclude dental implant therapy (including cardiovascular, hepatic, renal,&#xD;
             gastrointestinal, metabolic, neurologic, pulmonary, endocrine, autoimmune, or&#xD;
             psychiatric disorders)&#xD;
&#xD;
          -  Presence of conditions requiring chronic routine prophylactic use of antibiotics&#xD;
             (e.g., bacterial endocarditis, cardiac valvular anomalies, prosthetic joint&#xD;
             replacements)&#xD;
&#xD;
          -  Diabetic retinopathy requiring imminent or planned surgical intervention&#xD;
&#xD;
          -  Diabetic neuropathy of sufficient severity as to require treatment for control of&#xD;
             symptoms&#xD;
&#xD;
          -  Serum creatinine &gt; 1.6 mg/dl&#xD;
&#xD;
          -  AST (SGOT) or ALT (AGPT) &gt; 2 times upper limit of normal laboratory range&#xD;
&#xD;
          -  Hypertension, with or without medications, having a systolic pressure &gt; 185mm Hg or&#xD;
             diastolic pressure &gt; 105mm Hg&#xD;
&#xD;
          -  Patient has significant untreated oral infections or inflammatory lesions&#xD;
&#xD;
          -  Medical conditions requiring prolonged use of steroids&#xD;
&#xD;
          -  History of leukocyte dysfunction and deficiencies&#xD;
&#xD;
          -  History of bleeding disorders&#xD;
&#xD;
          -  Patients with history of renal failure&#xD;
&#xD;
          -  Patients with metabolic bone disorders&#xD;
&#xD;
          -  Physical handicaps that would interfere with the ability to perform adequate oral&#xD;
             hygiene&#xD;
&#xD;
          -  Use of any investigational drug or device within the 30 day period immediately prior&#xD;
             to implant surgery on study day 0&#xD;
&#xD;
          -  Patients who smoke &gt;10 cigarettes per day or cigar equivalents, or who chew tobacco&#xD;
&#xD;
          -  Conditions or circumstances, in the opinion of the investigator, which would prevent&#xD;
             completion of study participation or interfere with analysis of study results, such as&#xD;
             history of non-compliance, unreliability&#xD;
&#xD;
        Local Factors:&#xD;
&#xD;
          -  Signs of oral inflammation, such as untreated periodontitis around the teeth or&#xD;
             erosive lichen planus in the non-tooth associated areas&#xD;
&#xD;
          -  History of head/neck irradiation therapy&#xD;
&#xD;
          -  Presence of bone defects in the jaw preventing implant placement&#xD;
&#xD;
          -  Unhealed extraction sites (less than 4 months post extraction of teeth in intended&#xD;
             sites)&#xD;
&#xD;
          -  Bone surgery (bone grafts, guided tissue regeneration technique for bone enhancement)&#xD;
             less than 6 months prior to implant placement&#xD;
&#xD;
          -  Patients requiring bone grafting at the surgical sites at the time of surgery&#xD;
&#xD;
          -  Severe teeth grinding or clenching habits&#xD;
&#xD;
          -  Persistent intraoral infection&#xD;
&#xD;
          -  Lack of sufficient stability of the implant at surgery to allow for proper healing.&#xD;
&#xD;
          -  Patients with inadequate oral hygiene or unmotivated for adequate home care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>thomas w oates, dmd, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <results_first_submitted>October 27, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dental implant</keyword>
  <keyword>implant stabilization</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>glycated hemoglobin 8.0-12.0%</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dental Implant</title>
          <description>standard SLA surface and chemically-modified surface implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dental Implant</title>
          <description>standard SLA surface and chemically modified surface&#xD;
dental implant : standard SLA surface and modified dental implant : chemically modified surface</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Implant Stability Quotient (ISQ)</title>
        <description>resonance frequency analysis employed to determine implant stability quotient on a 1-100 point scale with 100 representing the greatest stability.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SLA Minimum ISQ HbA1c&lt;9.5</title>
            <description>standard SLA surface&#xD;
dental implant : standard SLA surface</description>
          </group>
          <group group_id="O2">
            <title>Modified SLA Minimum ISQ HbA1c&lt;9.5</title>
            <description>chemically modified surface&#xD;
modified dental implant : chemically modified surface</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Stability Quotient (ISQ)</title>
          <description>resonance frequency analysis employed to determine implant stability quotient on a 1-100 point scale with 100 representing the greatest stability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="5.6"/>
                    <measurement group_id="O2" value="61.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success of Implants</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Success of Implants</title>
            <description>Successful outcome of implant after one year</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success of Implants</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dental Implant</title>
          <description>standard SLA surface&#xD;
dental implant : standard SLA surface</description>
        </group>
        <group group_id="E2">
          <title>Modified Dental Implant</title>
          <description>chemically modified surface&#xD;
modified dental implant : chemically modified surface</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas W. Oates</name_or_title>
      <organization>University of Texas Health Science Center at San Antonio</organization>
      <phone>210-567-3590</phone>
      <email>oates@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

